Revenue from operations also saw an increase of 6%, rising to Rs.12,652.7 crore from Rs.11,940.84 crore YoY. Despite this overall revenue growth, the performance varied across different markets. Sales in the US formulation segment experienced a slight decline of 1%, totaling $466 million. This segment, however, still represents a substantial portion of Sun Pharma’s consolidated sales, accounting for over 31.1%.
On the other hand, sales of formulations in India increased by 16.4% to Rs.4,144.5 crore. India Formulations contributed almost 33.1% of the total consolidated sales, making this development noteworthy. Performing well as well were Emerging Markets, where sales increased 8.8% to $284 million, or 18.9% of total sales.
Conversely, during the quarter, sales of Active Pharmaceutical Ingredients (API) decreased by 8.3% to Rs.494.6 crore. In spite of this setback, Sun Pharma achieved noteworthy advancements in other domains. The company recently completed the acquisition of Taro minority shares, received clearance for Leqselvi in the US, and filed for Nidlegy in Europe, among other significant milestones. It is anticipated that these advancements will improve patient care and strengthen Sun Pharma’s innovative and generic business areas.Earnings before interest, taxes, depreciation, and amortization (EBITDA) increased 8.3% to Rs.3,607 crore from Rs.3,331.7 crore YoY, reflecting the company’s operating efficiency. Additionally, the EBITDA margin increased by 60 basis points to 28.5% from 27.9% the year before.
In Q1FY25, Sun Pharma invested Rs.794 crore in research and development (R&D), up from Rs.679.6 crore in Q1FY24. Six New Active Substances are presently undergoing clinical investigations, which is a testament to the robust specialist R&D pipeline that this funding supports. With 537 approved Abbreviated New Drug Applications (ANDAs) in the US market, 103 pending FDA clearance, and 28 tentative approvals, the company has a wide product range. Furthermore, the business has 14 New Drug Applications (NDAs) pending FDA clearance and 51 approved NDAs. Sun Pharma earned three approvals and filed one new ANDA during the quarter.
Investor confidence in Sun Pharma’s good performance and strategic direction is evident in the company’s shares, which were trading 1.02% higher at Rs.1,735.40 on the Bombay Stock Exchange (BSE) as of 2:35 pm.
SOURCE:
ETHEALTH WORLD
